Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MIST Stock Forecast 2025-2026
$1.73
Current Price
$92.49M
Market Cap
Buy 2
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to MIST Price Targets
+189.0%
To High Target of $5.00
+131.2%
To Median Target of $4.00
-42.2%
To Low Target of $1.00
MIST Price Momentum
+3.0%
1 Week Change
+34.1%
1 Month Change
+24.5%
1 Year Change
-26.7%
Year-to-Date Change
-37.1%
From 52W High of $2.75
+176.8%
From 52W Low of $0.63
📊 TOP ANALYST CALLS
Did MIST Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Milestone Pharma is one of their latest high-conviction picks.
Latest MIST Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, MIST has a neutral consensus with a median price target of $4.00 (ranging from $1.00 to $5.00). The overall analyst rating is Buy (7.0/10). Currently trading at $1.73, the median forecast implies a 131.2% upside. This outlook is supported by 2 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Brandon Folkes at HC Wainwright & Co., projecting a 189.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MIST Analyst Ratings
2
Buy
2
Hold
0
Sell
MIST Price Target Range
Low
$1.00
Average
$4.00
High
$5.00
Current: $1.73
Latest MIST Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MIST.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 5, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Assumes | $5.00 |
| Apr 1, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $10.00 |
| Mar 28, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| Mar 17, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| Jan 27, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| Oct 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| Aug 22, 2024 | Rodman & Renshaw | Brandon Folkes | Buy | Initiates | $9.00 |
| Aug 22, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| Jul 1, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| May 30, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| May 16, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| Mar 22, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| Mar 5, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $5.00 |
| Feb 26, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| Dec 27, 2023 | TD Cowen | Outperform | Maintains | $9.00 | |
| Aug 14, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| Jun 20, 2023 | Jefferies | Hold | Downgrade | $0.00 | |
| May 23, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| May 15, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
Milestone Pharmaceuticals Inc. (MIST) Competitors
The following stocks are similar to Milestone Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MIST
Milestone Pharmaceuticals
mkt cap
88.22M
Milestone Pharmaceuticals Inc. (MIST) Financial Data
Milestone Pharmaceuticals Inc. has a market capitalization of $92.49M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -307.3%.
Valuation Metrics
Market Cap
$92.49M
Enterprise Value
$114.46M
P/E Ratio
0.0x
PEG Ratio
-2.0x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+48.7%
Current Ratio
4.7x
Debt/Equity
-9.1x
ROE
-307.3%
ROA
-41.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Milestone Pharmaceuticals Inc. (MIST) Business Model
About Milestone Pharmaceuticals Inc.
What They Do
Develops innovative cardiovascular disease treatments.
Business Model
The company focuses on developing and commercializing treatments for cardiovascular diseases, specifically targeting conditions like paroxysmal supraventricular tachycardia (PSVT). It makes money through the research, development, and potential sales of its investigational drugs, particularly those that offer rapid-onset therapy for patients experiencing acute cardiovascular events.
Additional Information
Milestone Pharmaceuticals is recognized for its contributions to healthcare and biotechnology, with a strong emphasis on addressing unmet medical needs. The company aims to improve patient outcomes and quality of life through its innovative therapeutic options, positioning itself as a key player in the pharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
33
CEO
Mr. Joseph G. Oliveto M.B.A.
Country
Canada
IPO Year
N/A
Website
www.milestonepharma.comMilestone Pharmaceuticals Inc. (MIST) Latest News & Analysis
Latest News
Quick Summary
Milestone Pharmaceuticals submitted its response to the FDA regarding the Complete Response Letter for its NDA of CARDAMYST™ (etripamil) nasal spray, aimed at treating PSVT in adults.
Why It Matters
Milestone Pharmaceuticals' FDA response could impact the approval timeline and market potential for CARDAMYST™, influencing stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Milestone Pharmaceuticals (Nasdaq: MIST) executives will present at the Jefferies Healthcare Conference in New York from June 3-5, 2025.
Why It Matters
Milestone Pharmaceuticals' participation at a major healthcare conference signals potential updates on financial health and strategic direction, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Milestone Pharmaceuticals (MIST) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects.
Why It Matters
Milestone Pharmaceuticals' upgrade to Zacks Rank #2 indicates strong earnings potential, signaling positive market sentiment and possibly driving share price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Milestone Pharmaceuticals Inc. is addressing CRL Manufacturing issues and has requested a Type A meeting. No safety or efficacy concerns were raised by the FDA. Q1 2025 financial results reported.
Why It Matters
Progress in resolving manufacturing issues and lack of safety concerns from the FDA may boost Milestone Pharmaceuticals' stock value and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Seeking Alpha added 30 new analysts in March, featuring diverse stock picks across industries. Notable top picks include C3.ai, Robinhood, Central Puerto, CF Industries, and Kyndryl.
Why It Matters
The addition of 30 analysts and their diverse stock picks signals potential market insights and investment opportunities across various sectors, influencing investor strategies and portfolio decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Milestone Pharmaceuticals' PSVT nasal spray faces a setback with a FDA Complete Response Letter (CRL). The company is working with regulators to address the issues.
Why It Matters
FDA setbacks can delay product launches and revenue, impacting Milestone Pharmaceuticals’ stock price and investor confidence. Resolution of CRL issues is crucial for future growth prospects.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About MIST Stock
What is Milestone Pharmaceuticals Inc.'s (MIST) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Milestone Pharmaceuticals Inc. (MIST) has a median price target of $4.00. The highest price target is $5.00 and the lowest is $1.00.
Is MIST stock a good investment in 2025?
According to current analyst ratings, MIST has 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MIST stock?
Wall Street analysts predict MIST stock could reach $4.00 in the next 12 months. This represents a 131.2% increase from the current price of $1.73. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Milestone Pharmaceuticals Inc.'s business model?
The company focuses on developing and commercializing treatments for cardiovascular diseases, specifically targeting conditions like paroxysmal supraventricular tachycardia (PSVT). It makes money through the research, development, and potential sales of its investigational drugs, particularly those that offer rapid-onset therapy for patients experiencing acute cardiovascular events.
What is the highest forecasted price for MIST Milestone Pharmaceuticals Inc.?
The highest price target for MIST is $5.00 from Brandon Folkes at HC Wainwright & Co., which represents a 189.0% increase from the current price of $1.73.
What is the lowest forecasted price for MIST Milestone Pharmaceuticals Inc.?
The lowest price target for MIST is $1.00 from at , which represents a -42.2% decrease from the current price of $1.73.
What is the overall MIST consensus from analysts for Milestone Pharmaceuticals Inc.?
The overall analyst consensus for MIST is neutral. Out of 6 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are MIST stock price projections?
Stock price projections, including those for Milestone Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 3:27 AM UTC